R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry

Keywords

Pharmaceutical industry, Industrial organization, Business, Economics, Microeconomics

References

• New drug development in the United States from 1963 to 1992Santiago Bellés Medall — 1994
• How health care reform affects pharmaceutical research and developmentAnna Cook, Philip Webre — 1994
• Innovation and Growth: Schumpeterian PerspectivesStanford L. Levin, F. M. Scherer — 1986
• Market Structure and Technological ChangeWilliam L. Baldwin, John T. Scott — 1987
• Pricing, Profits, and Technological Progress in the Pharmaceutical IndustryF. M. Scherer — 1993
• Returns to Scale in Research in the Ethical Pharmaceutical Industry: Some Further Empirical EvidenceAlan S. Angilley — 1973
• Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActHenry G. Grabowski, John M. Vernon — 1992
• "Innovation in the Pharmaceutical Industry".David Schwartzman — 1978
• Returns to R&D on new drug introductions in the 1980s.Henry G. Grabowski, John M. Vernon — 1994
• Do Important Drugs Reach the Market SoonerDavid Dranove, David Meltzer — 1994
• The Empirical Basis for the Discovery of New TherapiesJames S. Goodwin — 2015
• Technical Change and Firm Size: The Pharmaceutical IndustryJohn M. Vernon, Peter Gusen — 1974
• Success rates for new drugs entering clinical testing in the United StatesJoseph A. DiMasi — 1995
• Innovation and Structural Change in Pharmaceuticals and BiotechnologyHenry G. Grabowski, John M. Vernon — 1994
• Research Expenditures and the Discovery of New DrugsElizabeth J. Jensen — 1987
• A New Look at the Returns and Risks to Pharmaceutical R&DHenry G. Grabowski, John M. Vernon — 1990
• Setting the record straight: The office of technology assessment report—pharmaceutical R&D costs, risks, and rewardsAlice M. Sapienza — 1993
• Innovative productivity and returns to scale in the pharmaceutical industrySamuel B. Graves, Nan S. Langowitz — 1993
• Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?Bronwyn H. Hall — 1992
• Cost of innovation in the pharmaceutical industry.Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski — 1991

Cited by

• PharmaMar: una aplicación de la teoría de opciones reales a la valoración de empresas farmaceúticasDiego Piñeiro Groba, Ángel León — 2004
• Technology Trends in Drug Discovery and Development: Implications for the Development of the Pharmaceutical Industry in AustraliaKim Sweeny — 2002
• Bioinformatics solutions for confident identification and targeted quantification of proteins using tandem mass spectrometryJennifer A. Cham — 2009
• Clinical trials and tribulations: implementation processes in schizophrenia research outcome.Susan E. Mason, Paul C. Bermanzohn, Samuel G. Siris — 1998
• REAL OPTIONS IN BIOTECHNOLOGICAL FIRMS VALUATION. AN EMPIRICAL ANALYSIS OF EUROPEAN FIRMS.Gracia Rubio Martín, Prosper Lamothe Fernández — 2006
• Wald Revisited: The Optimal Level of ExperimentationGiuseppe Moscarini, Lones Smith — 1998
• THE OPTIMALL EVELOF EXPERIMENTATIONGiuseppe Moscarini, Lones Smith — 2001
• Paths to Creating Value in Pharmaceutical MergersDavid J. Ravenscraft, William F. Long — 2000
• The Market for Professional Services in IndonesiaIlias G. Basioudis, Fifi Fifi — 2004
• The cost of drug development: a systematic review.Steve Morgan, Paul Grootendorst, Joel Lexchin — 2011
• Strategic groups in the biopharmaceutical industry: implications for performance.Zeynep Erden, Georg von Krogh, Cecilia Nytorp — 2009
• Size, R&D productivity and Decision StylesJosé Lejarraga, Ester Martínez Ros — 2014
• Experience and scale and scope economies: Trade-offs and performance in development.Jeffrey T. Macher, Christopher Boerner — 2006
• Executive Summary: White Paper on Four Areas of Relevance to New Drug Development and Review in the United StatesKenneth I. Kaitin — 1995
• How Much Does Expertise Reduce Behavioral Biases? The Case of Anchoring Effects in Stock Return EstimatesMarkku Kaustia, Eeva Alho, Vesa Puttonen — 2008
• Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover productsHans H. Bauer, Marc Fischer — 2000
• Risks in new drug development: Approval success rates for investigational drugsJoseph A. DiMasi — 2001
• New drug development in the United States from 1963 to 1999Joseph A. DiMasi — 2001
• Pharmaceutical R&D Performance by Firm Size: Approval Success Rates and Economic ReturnsJoseph A. DiMasi — 2014
• Regulatory Dependence and Scientific Advisory BoardsJay Chok — 2009

Related papers

• Fiscal Policy and the Terms of Trade in an Analytical Two-Country Dynamic ModelMarcelo Bianconi — 2003
• Monetary-fiscal policy interactions and the price level:Background and beyondEric M. Leeper, Tack Yun — 2006
• ACCELERATING INFLATION OR RISING UNEMPLOYMENT ‐IS THERE AN ALTERNATIVE?Winfried Vogt — 1996
• Unemployment as excess supply of labor: Implications for wage and price inflationMiguel Casares — 2010
• Stabilisation, Policy Targets and Unemployment in Imperfectly Competitive EconomiesGeorge J. Bratsiotis, Christopher Martin — 1999
• Unemployment Insurance in Macroeconomic StabilizationRohan Kekre — 2022
• Competition in the Pharmaceutical IndustryBianca Piachaud — 2004
• What drives the export performance of small and medium-sized subcontracting firms? A study of Korean manufacturersJae‐Jin Kim, Martin Hemmert — 2016